Linda Bolton-Weiser

James Salera

Jim Salera

Doug Lane

Douglas Lane

- Medifast reported **Q3 2025 revenue of $89.4 million**, a **36.2% decrease** compared to the prior year, and a **net loss of $2.3 million**, resulting in a **loss of $0.21 per diluted share**.  **[0000910329_2228548_4]** 
- The company ended Q3 2025 with approximately **19,500 active earning OPTAVIA coaches**, a **35% decrease** from Q3 2024, with average revenue per coach at **$4,585**, down 1.9% year-over-year.  **[0000910329_2228548_4]** 
- Medifast is strategically evolving to become a leader in **metabolic health**, with plans to launch significant product innovations next year that will replace the current Essential product line.  **[0000910329_2228548_2]** **[0000910329_2228548_3]** **[0000910329_2228548_4]** 
- For **Q4 2025**, Medifast anticipates revenue to range from **$65 million to $80 million** and a loss per share between **$0.70 and $1.25**.  **[0000910329_2228548_4]** 
- The company maintains a strong financial position with **$173.5 million in cash, cash equivalents, and investments** and no interest-bearing debt as of September 30, 2025.  **[0000910329_2228548_4]**

Medifast Reports Q3 2025 Financial Results and Strategic Shift to Metabolic Health

- Medifast reported **Q3 2025 revenue of $89.4 million**, a **36.2% decrease** from the prior year, resulting in a **net loss of $2.3 million** or **$0.21 loss per diluted share**.  **[910329_ca35f88c64dc4f049cec81fb61e5d370_0]** **[910329_ca35f88c64dc4f049cec81fb61e5d370_1]** 
- The decline was primarily driven by a **35.0% decrease** in active earning OPTAVIA coaches to **19,500**, attributed to challenges with client acquisition due to the growing acceptance of GLP-1 medications for weight loss.  **[910329_ca35f88c64dc4f049cec81fb61e5d370_0]** 
- The company maintains a **strong balance sheet** with **$173.5 million in cash, cash equivalents, and investment securities** and **no debt** as of September 30, 2025.  **[910329_ca35f88c64dc4f049cec81fb61e5d370_0]** **[910329_ca35f88c64dc4f049cec81fb61e5d370_2]** 
- For **Q4 2025**, Medifast expects revenue to be in the range of **$65 million to $80 million** and diluted loss per share to be in the range of **$0.70 to $1.25**.  **[910329_ca35f88c64dc4f049cec81fb61e5d370_2]**

Medifast Announces Third Quarter 2025 Financial Results

- Medifast reported third quarter 2025 **revenue of $89.4 million**, a **36.2% decrease** from the third quarter of 2024.  **[910329_0001628280-25-048251_medq32025earningsrelease.htm:0]** **[910329_0001628280-25-048251_medq32025earningsrelease.htm:1]** 
- The company experienced a **net loss of $2.3 million**, or **$0.21 loss per diluted share**, for Q3 2025, compared to net income in the prior year period.  **[910329_0001628280-25-048251_medq32025earningsrelease.htm:0]** **[910329_0001628280-25-048251_medq32025earningsrelease.htm:2]** 
- The number of active earning OPTAVIA coaches **decreased 35.0% to 19,500** in Q3 2025, primarily due to client acquisition challenges.  **[910329_0001628280-25-048251_medq32025earningsrelease.htm:1]** 
- Medifast maintained a strong balance sheet with **$173.5 million** in cash, cash equivalents, and investment securities and **no debt** as of September 30, 2025.  **[910329_0001628280-25-048251_medq32025earningsrelease.htm:0]** **[910329_0001628280-25-048251_medq32025earningsrelease.htm:3]** 
- For the fourth quarter of 2025, the company expects revenue to be in the range of **$65 million to $80 million** and diluted loss per share to be in the range of **$0.70 to $1.25**.  **[910329_0001628280-25-048251_medq32025earningsrelease.htm:3]**

- Medifast reported **Q3 2025 revenue of $89 million**, an **operating loss of ($4.1 million)**, and a **loss per share of ($0.21)**.  **[0000910329_2228319:4]**  The gross profit margin was **69.5%**, representing a **590 basis point decline** compared to Q3 2024.  **[0000910329_2228319:4]** 
- The company maintained a strong financial position, being **debt-free** with **$174 million in cash and investments** as of September 30, 2025, which is a **2% increase** from the prior year period.  **[0000910329_2228319:4]** 
- Coach productivity trends stabilized, with revenue per active earning coach declining **2% year-over-year** and **1% quarter-over-quarter**, and the company reported **19,500 active earning coaches**.  **[0000910329_2228319:4]** 
- Medifast is strategically transforming from a weight loss company to a metabolic health leader, introducing "Metabolic Synchronization" and planning a new product line launch in **2026**.  **[0000910329_2228319:5]** **[0000910329_2228319:9]** 
- For **Q4 2025**, Medifast provided guidance anticipating revenue between **$65 million and $80 million** and a loss per share between **($0.70) and ($1.25)**.  **[0000910329_2228319:10]**

MEDIFAST (MED)